论文部分内容阅读
目的:探讨贝那普利联合阿托伐他汀治疗慢性心力衰竭临床疗效及对患者血清炎症因子水平的影响。方法:收集我院2014年12月~2016年5月确诊为慢性心力衰竭的患者120例,随机分为观察组和对照组,各60例。对照组采用口服贝那普利治疗,观察组采用贝那普利联合阿托伐他汀治疗。观察并比较两组患者治疗前后左室收缩末期容积指数(LVESVI)、左室舒张末期容积指数(LVEDVI)、左心室舒张末期内径(LVEDD)、左心射血分数(LVEF)及血清NT-proBNP,hs-CRP,TNF-α,白介素-6(IL-6)及白介素-8(IL-8)水平的变化情况。结果:观察组有效率优于对照组,差异具有统计学意义(P<0.05);治疗后,两组患者Pro-BNP、LVEDD、E/A均降低,且观察组低于对照组(P<0.05);治疗后,两组患者LVEF升高,且观察组高于对照组(P<0.05);两组患者治疗后血清hs-CRP,TNF-α,IL-6及IL-8水平均降低,且观察组低于对照组(P<0.05)。结论:贝那普利联合阿托伐他汀治疗对慢性心力衰竭患者进行治疗,疗效显著,患者炎症反应小,是一种安全有效的治疗方法。
Objective: To investigate the clinical efficacy of benazepril combined with atorvastatin in the treatment of chronic heart failure and its effect on the levels of serum inflammatory cytokines. Methods: A total of 120 patients with chronic heart failure who were diagnosed as chronic heart failure from December 2014 to May 2016 in our hospital were randomly divided into observation group and control group, with 60 cases each. The control group was treated with oral benazepril and the observation group with benazepril combined with atorvastatin. The left ventricular end systolic volume index (LVESVI), left ventricular end-diastolic volume index (LVEDVI), left ventricular end diastolic dimension (LVEDD), left ventricular ejection fraction (LVEF) and serum NT-proBNP , hs-CRP, TNF-α, interleukin-6 (IL-6) and interleukin-8 (IL-8) Results: The effective rate of the observation group was better than that of the control group (P <0.05). After treatment, the Pro-BNP, LVEDD and E / A of the two groups were decreased and the observation group was lower than the control group (P < 0.05). After treatment, LVEF in both groups increased, and the observation group was higher than the control group (P <0.05). The serum hs-CRP, TNF-α, IL-6 and IL- , And the observation group was lower than the control group (P <0.05). Conclusion: Benazepril combined with atorvastatin treatment of patients with chronic heart failure, a significant effect, the patient’s inflammatory response is small, is a safe and effective treatment.